Brainstorm Cell Therapeutics (BCLI) released data from a Phase 2 study assessing NurOwn mesenchymal stem cells for the treatment of patients with amyotrophic lateral sclerosis (ALS). Treatment with NurOwn consistently beat placebo, although the difference at most time points (2 weeks - 24 weeks) fell short of statistical significance. Also the treatment effect rapidly diminished over time. The company plans to meet with the FDA to discuss the results. A larger confirmatory study is the next step.